In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...

One in five Irish people said they would not take a traditional vaccine, a worldwide research project found. A further one in ...

South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...

The Slovak government halted purchases of COVID-19 vaccines on Wednesday pending a review of their safety by the Slovak ...

SK Bioscience announced Wednesday that it has secured a definitive legal victory in its patent invalidation suit against Moderna, successfully challenging the biotech giant’s Korean patent related to ...

SEOUL, April 23 (Yonhap) -- SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has ...